Cell and Gene Outsourcing

1. What Is ISO 21973 And Why It Matters For Cell And Gene Therapy 12/29/2025

   ISO 21973 establishes global best practices for transporting cell and gene therapies, ensuring quality, safety, and consistency across complex supply chains critical to patient outcomes.

2. Setting The Benchmark For Quality In Cell And Gene Therapy Logistics 12/29/2025

   ISO 21973 defines global best practices for transporting cell and gene therapies, ensuring safety, quality, and consistency across complex supply chains vital to patient care.

    

3. Driving Compliance And Standardization In CGT Supply Chains 12/29/2025

   Standardization and compliance in CGT supply chains are critical for minimizing risk, ensuring product integrity, and meeting regulatory demands across global manufacturing and distribution networks.

4. Viral Clearance Testing For Biologics, Vaccines & AAV Therapies 12/23/2025

   Viral clearance protects patients by validating virus removal and inactivation in biologics manufacturing, meeting global standards through rigorous, audit-ready studies and expert oversight.

    

5. CGT Industrialization Starts With CDMO Alignment 12/19/2025

   Fragmented processes are stalling progress. By aligning CDMOs through transparency and standards, developers can move past the COGS obsession and stabilize the supply chain.

6. Why Efficiency In Multi-Modal CGT Manufacturing Is About Execution, Not Just Cost 12/18/2025

   Our recent Cell & Gene Live, Driving Efficiency, Reducing Costs in Multi-Modal CGT Manufacturing, explored how developers and CDMOs are navigating multi-modal manufacturing decisions, balancing cost, capacity, risk, and long-term commercial viability.

7. Viral Vectors: The Backbone Of Cell And Gene Therapy 12/16/2025

   Viral vectors are the indispensable backbone of genetic medicine. Learn the fundamental trade-offs and manufacturing strategies for large-scale production of AAV and lentiviral delivery systems.

8. November 2025 — CDMO Opportunities And Threats Report 12/16/2025

   Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.

9. Minaris Advanced Therapies Overview 12/15/2025

   Global cell and gene therapy CDMO providing GMP manufacturing, testing, and development services with commercial success, regulatory expertise, and advanced multi‑modality capabilities.

10. Cell Therapy Lot Release Package 12/15/2025

    Comprehensive cGMP-compliant cell therapy lot release testing includes identity, potency, safety, and characterization assays, ensuring regulatory compliance and timely product release for advanced therapies.